Bicycle Therapeutics (NASDAQ:BCYC) plc is a clinical-stage biotechnology company that leverages a proprietary platform to design and develop bicyclic peptides as novel therapeutics. Founded in 2009 and headquartered in Cambridge, U.K., the company applies its chemistry-driven discovery engine to produce highly selective and stable molecules capable of modulating challenging targets. By constraining peptides into rigid three-dimensional structures, Bicycle Therapeutics’ platform seeks to combine the binding specificity of antibodies with the tissue penetration and manufacturing advantages of small molecules.
The company’s pipeline spans oncology and immunology, with lead candidates in both clinical and preclinical development. Its most advanced program, BT8009, is designed as a tumor-binding Bicycle™ therapeutic targeting Nectin-4 in solid tumors. Additional oncology assets include Bicycle Drug Conjugates aimed at delivering cytotoxic payloads directly to cancer cells, and personalized immuno-modulatory constructs intended to recruit immune effectors to tumor sites. Beyond oncology, preclinical efforts explore inflammatory and metabolic indications using customized bicyclic peptide scaffolds.
Bicycle Therapeutics serves global markets through operations in Europe and North America. The company maintains its R&D headquarters in Cambridge, U.K., and operates a U.S. subsidiary in Boston, Massachusetts, to support clinical trial execution and strategic collaborations. Partnerships with established pharmaceutical and biotech firms have augmented Bicycle’s resource base and extended its reach into new therapeutic areas, underpinning shared research programs and co-development initiatives.
The management team brings together experience in drug development, chemistry, and commercial strategy. Bicycle is led by a seasoned executive team with backgrounds at major biopharmaceutical companies and venture-backed startups. Under their guidance, the company continues to advance its novel platform, with a focus on translating early research into clinical candidates and forging collaborations that accelerate the path to patient impact.
